CN101147736A - Composition capable of reducing blood lipoid and lowering cholesterol - Google Patents
Composition capable of reducing blood lipoid and lowering cholesterol Download PDFInfo
- Publication number
- CN101147736A CN101147736A CNA2007101654949A CN200710165494A CN101147736A CN 101147736 A CN101147736 A CN 101147736A CN A2007101654949 A CNA2007101654949 A CN A2007101654949A CN 200710165494 A CN200710165494 A CN 200710165494A CN 101147736 A CN101147736 A CN 101147736A
- Authority
- CN
- China
- Prior art keywords
- policosanol
- omega
- blood fat
- fat reducing
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a medicine composition capable of effectively reducing lipid content and cholesterol content. Said medicine composition contains (by weight portion) 200-1000 portions of Omega-3 ocean oil and 2-10 portions of priol. Besides, said medicine composition also has the action for resisting blood-platelet agglutination.
Description
Technical field
The present invention relates to a kind of health product, especially relate to a kind of blood fat reducing, hypocholesterolemic compositions.
Background technology
The Omega-3 marine oil comprises seal oil and fish oil, wherein contains abundant Omega-3 fatty acid, particularly many carbon of Omega-3 unsaturated fatty acid.Many carbon of Omega-3 unsaturated fatty acid is by EPA (EPA), 100% natural mixture that clupanodonic acid (DPA) and docosahexenoic acid (DHA) are formed.Many carbon of Omega-3 unsaturated fatty acid (PUFAs) can prevent coronary heart disease, has anti-heart rhythm disorders, anti-inflammatory and antiplatelet coagulation.Many carbon of Omega-3 unsaturated fatty acid can also reach the content of reduction triglyceride etc. by fat is carried out modification, is to safeguard healthy necessary factor.
Policosanol (Policosanol) is the higher fatty acid family alcohol mixture that purification comes out from Caulis Sacchari sinensis, Testa oryzae, Cera Flava, curd, Herba Spinaciae or Herba bromi japonici.Policosanol has the cholesterol reducing ability, and concrete effect is to reduce blood total cholesterol and low-density lipoprotein cholesterol (LDL-C) and improve HDL-C (HDH-C).Policosanol is gentle to the effect of triglyceride (TG) and differs successive.
Omega-3 marine oil and policosanol all have the effect of blood fat reducing, cholesterol reducing, but do not see the applied in any combination of two kinds of materials.
Summary of the invention
Technical problem to be solved by this invention is, a kind of novel blood fat reducing, hypocholesterolemic compositions safe, without any side effects of better effects if are provided, be mainly used in the Type II hypercholesterolemia, comprise IIa subtype (total serum liquid cholesterol and LDL-C level increase) and IIb subtype (miscellaneous hypercholesterolemia).
The technical solution adopted for the present invention to solve the technical problems is: a kind of blood fat reducing, hypocholesterolemic compositions are provided, mainly comprise Omega-3 marine oil and policosanol.
Wherein, the weight portion of Omega-3 marine oil is 200-1000 part, and the weight portion of policosanol is 2-10 part.
As preferably, the weight portion of Omega-3 marine oil is 400-600 part, and the weight portion of policosanol is 4-6 part.
As preferably, the weight portion of Omega-3 marine oil is 500 parts, and the weight portion of policosanol is 5 parts.
The acid of many carbon of Omega-3 unsaturated fatty acid is the key factor of cell membrane composition, also is the key factor that deoxy prostaglandin is produced.Deoxy prostaglandin is a material that similar hormone is the same, is our intravital cell balance check system.
Many carbon of Omega-3 unsaturated fatty acid is the mixture of EPA, DHA and three kinds of natural unsaturated fatty acids of DPA.
Wherein, EPA (EPA) plays a very important role in cardiovascular system, and it can reduce inflammation and thrombosis, and in blood control triglyceride and cholesterol level and prevent arteriosclerosis (arterial wall become mix hardening).
Docosahexenoic acid (DHA) is the necessary component of brain, nerve and eye tissue, to development baby's visual acuity and motor skill particular importance.
Clupanodonic acid (DPA), main effect are to keep the blood vessel wall softness, reduce fatty spew (deposition of arterial blood tube wall lactone fat material), prevent thrombosis.
Acting as of many carbon of Omega-3 unsaturated fatty acid acid: reduce lipid; By safeguarding that arterial wall elasticity brings high blood pressure down, can reduce 5-10% to hypertensive patient's blood pressure; By promote to improve that nitrogen oxide relies on and nitrogen oxide independently vasodilation promote loosening of endotheliocyte; Reduce the risk that blood vessel wall further is subjected to mechanical failure, in order to avoid cause arteriosclerosis; By stoping smooth muscle cell multiplication, revise the synthetic of deoxy prostaglandin and reducing the generation that the inhibiting influence of cell adhesion molecule stops arteriosclerosis and inflammation; The viscosity (toughness) that reduces platelet and hemocyte is in order to avoid cause local inflammation; Have anti-thrombosis function and influence the hemostasis system function (reduce hematoblastic respond, moderately prolong the hemorrhage time and the reduction blood plasma viscosity); By increasing parasympathetic mediation effect, change cytokine content and the influence of other factors being reduced heart rate; The generation of inflammation-inhibiting production of cytokines (interleukin, neoplasm necrosis factor) and mitogen; By increasing eicosapentaenoic acid, clupanodonic acid and the docosahexenoic acid content in the heart oils and fats reduces the ARR generation of pernicious ventricle; Protection and prevention immune system overreaction.
Policosanol (Policosanol) comprises octacosane alcohol (octacosanol), dotriacontane alcohol (dotriacontanol), triacontanol (tricontanol), tetracosanol (tetracosanol), inearnatyl alcohol (tetratriacontanol), hexacosanol (hexacosanol), heptacosanol (heptacosanol) and nonacosanol (nonocosanol), the main effect of policosanol is: 1, stop cholesterol earliest period synthetic in liver by the activity that changes acetyl.Because 80% cholesterol is to produce,, then just reduced the human body total cholesterol level naturally if stoped its synthesizing in liver in liver.2, reduce the content of cholesterol in heart, liver and fatty tissue.3, the serum content among the reduction pre-polymerization thromboxane A2 improves the content that resists polymeric prostaglandin prostacyclin; Prevent and reverse arteriosclerotic infringement and thrombosis, prevent the propagation of tunica intima thickening and smooth muscle; Its high efficiency antioxidant prevents the Oxidation of low density lipoprotein, LDL (LDL) effectively.
As preferably, the Omega-3 marine oil is seal oil or fish oil or both combinations.Because contain abundant many carbon of Omega-3 unsaturated fatty acid acid in seal oil and the fish oil.By contrast, many carbon of Omega-3 unsaturated fatty acid acid content is 20-25% in the seal oil, and than most fish oil content height, and seal oil do not contain cholesterol, and therefore, seal oil is more effective many carbon of Omega-3 unsaturated fatty acid acid source.In addition, the acid of many carbon of Omega-3 unsaturated fatty acid can better enter health in the seal oil, because it is the same in EPA, the DPA of the acid of many carbon of Omega-3 unsaturated fatty acid in the seal oil, DHA ratio and the human body, the terminal position (sn-1 and sn-3) that is positioned at the triacylglycerol molecule also with human body in the same, easier by digestion with better assimilate.Therefore, more preferably seal oil among the present invention.
As preferably, described policosanol is the higher fatty acid family alcohol mixture that purification comes out from the wax of Caulis Sacchari sinensis.
As preferably, described policosanol is the higher fatty acid family alcohol mixture that purification comes out from Caulis Sacchari sinensis, Testa oryzae, Cera Flava, curd, Herba Spinaciae and Herba bromi japonici.
The present invention effectively combines Omega-3 marine oil and policosanol, interacts, and makes its effectiveness addition.Many carbon of Omega-3 unsaturated fatty acid is by carrying out the content that modification reduces triglyceride to fat, but the people of hypercholesterolemia has the probability that slightly increases low density lipoprotein, LDL (LDL) cholesterol iff additional Omega-3; Policosanol is gentle to the effect of triglyceride (TG) and differs successive, but well-known with cholesterol reducing.It is that cholesterol synthetic earliest period in liver is controlled that policosanol stops the synthetic mechanism of cholesterol.Policosanol is by stimulating the beta oxidation, promote the synthetic of many carbon of Omega-3 unsaturated fatty acid, therefore, the combination of two kinds of natural materials, further promote eicosapentaenoic acid (EPA), the generation of clupanodonic acid (DPA) and docosahexenoic acid (EPA) and the consecutive reaction of anti-inflammatory in cardiovascular.
In sum,, can promote the synthetic of many carbon of Omega-3 unsaturated fatty acid acid, increase the content of many carbon of Omega-3 unsaturated fatty acid acid in each tissue of health by the combination of Omega-3 marine oil and policosanol; And further promote eicosapentaenoic acid (EPA), the generation of clupanodonic acid (DPA) and docosahexenoic acid (EPA) and the consecutive reaction of anti-inflammatory in cardiovascular; Reach the effect of blood fat reducing, cholesterol reducing.The invention has the beneficial effects as follows: can more effective cholesterol reducing level (reduce serum total cholesterol, low-density lipoprotein cholesterol content, cholesterol reducing is the content of (as liver, heart and fatty tissue) in tissue), reduce the triglycerides level, simultaneously also reduce platelet and condense, inflammation and endothelium infringement; And antiplatelet condenses.Simultaneously, product of the present invention prevents to reverse arteriosclerotic infringement and thrombosis, prevents the propagation of inner membrance thickening and smooth muscle, and then promotes the general health level of human body.
Description of drawings
Fig. 1 is linolenic acid serial reaction figure.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is described.
Embodiment 1 linolenic acid serial reaction figure.
Referring to Fig. 1, after C18:3n (Alpha's linolenic acid) enters human body, id reaction by human body generates the fatty acid prolonging enzyme, under the effect of fatty acid prolonging enzyme, make its phosphorus content increase to 20 by 18, pass through the reaction of human body self and the effect of fatty acid prolonging enzyme etc. again, generate the C24:6.n-3 nisioic acid, the material of this 24C of containing is a human body and unwanted, at this moment, makes it be converted into useful C22:6.n-3 (docosahexenoic acid) DHA through the Beta Oxidation.
Because policosanol has the effect that stimulates the Beta oxidation, therefore, policosanol can play the effect that stimulates the Beta oxidation in this process, thereby promote the synthetic of many carbon of Omega-3 unsaturated fatty acid, further promote eicosapentaenoic acid (EPA), clupanodonic acid (DPA) and docosahexenoic acid (DHA) generate.
Embodiment 2 Omega-3 and policosanol mixture double-blind trial
80 patients that suffer from the Type II hypercholesterolemia have been carried out the double-blind trial design studies.Patient is divided into four groups, takes Omega-3 and policosanol mixture and Omega-3 and the placebo mixture of 5mg and 10mg every day for respectively every group of patient.After 8 weeks, the patient LDL cholesterol level of taking 5mg and 10mg Omega-3 and policosanol mixture every day significantly reduces 21.2% and 24.4% respectively; But the patient who takes Omega-3 and placebo mixture every day does not have this effect.Patient's T-CHOL of taking 5mgOmega-3 and policosanol mixture every day significantly reduce (12.7%, p＜0.01=and triglycerides (13.6%, p＜0.05=, simultaneously HDL-C (high density lipoprotein) significantly increases (+14.4%; P＜0.01=.(15.3%, p＜0.001=and triglycerides (14.7%, p＜0.01) significantly increase HDL-C (+15 simultaneously to take the also remarkable hypercholesterolemia reducing of 10mg Omega-3 and policosanol mixture every day.5%; P＜0.01=; Obey every day 10mg Omega-3 and placebo mixture significantly reduce triglycerides (14.2%, p＜0.05=, but other lipid variable is not had material impact.
Blood fat reducing of the present invention, hypocholesterolemic compositions can add appropriate amount of auxiliary materials and make various dosage forms.
Use following composition to prepare soft capsule according to conventional processes:
Get seal oil 60g, policosanol 0.6g adds an amount of capsule adjuvant, makes every and contains seal oil 500mg, 120 of the soft capsules of policosanol 5mg; Take evening every day, each 4.
Embodiment 4 preparation of soft capsule
Get seal oil 36g, policosanol 0.48g adds an amount of capsule adjuvant, makes every and contains seal oil 300mg, 120 of the soft capsules of policosanol 4mg; Take evening every day, each 4.
Embodiment 5 preparation of soft capsule
Get fish oil 96g, policosanol 0.7g adds an amount of capsule adjuvant, makes every and contains fish oil 800mg, 120 of the soft capsules of policosanol 6mg; Take evening every day, each 4
Embodiment 6 preparation of soft capsule
Get seal oil 48g, fish oil 24g, policosanol 0.72g adds an amount of capsule adjuvant, makes every and contains seal oil 400mg, fish oil 200mg, 120 of the soft capsules of policosanol 6mg.Take evening every day, each 4.
Above content be in conjunction with concrete preferred implementation to further describing that the present invention did, can not assert that concrete enforcement of the present invention is confined to these explanations.For the general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, can also make some simple deduction or replace, all should be considered as belonging to protection scope of the present invention.
Claims (7)
1. a blood fat reducing, hypocholesterolemic compositions, it is characterized in that: described compositions comprises Omega-3 marine oil and policosanol.
2. a kind of blood fat reducing according to claim 1, hypocholesterolemic compositions is characterized in that: the weight portion of described Omega-3 marine oil is 200-1000 part, and the amount of described policosanol is 2-10 part.
3. a kind of blood fat reducing according to claim 2, hypocholesterolemic compositions is characterized in that: the weight portion of described Omega-3 marine oil is 400-600 part, and the weight portion of described policosanol is 4-6 part.
4. a kind of blood fat reducing according to claim 3, hypocholesterolemic compositions is characterized in that: the weight portion of described Omega-3 marine oil is 500 parts, and the weight portion of described policosanol is 5 parts.
5. a kind of blood fat reducing according to claim 1, hypocholesterolemic compositions is characterized in that: described Omega-3 marine oil is seal oil and/or fish oil.
6. a kind of blood fat reducing according to claim 1, hypocholesterolemic compositions is characterized in that: described policosanol is the higher fatty acid family alcohol mixture that purification comes out from Caulis Sacchari sinensis.
7. a kind of blood fat reducing according to claim 1, hypocholesterolemic compositions is characterized in that: described policosanol is the higher fatty acid family alcohol mixture that purification comes out from Caulis Sacchari sinensis, Testa oryzae, Cera Flava, curd, Herba Spinaciae or Herba bromi japonici.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101654949A CN101147736A (en) | 2007-10-30 | 2007-10-30 | Composition capable of reducing blood lipoid and lowering cholesterol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101654949A CN101147736A (en) | 2007-10-30 | 2007-10-30 | Composition capable of reducing blood lipoid and lowering cholesterol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101147736A true CN101147736A (en) | 2008-03-26 |
Family
ID=39248508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101654949A Pending CN101147736A (en) | 2007-10-30 | 2007-10-30 | Composition capable of reducing blood lipoid and lowering cholesterol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101147736A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101982163A (en) * | 2010-10-27 | 2011-03-02 | 中国科学院西双版纳热带植物园 | Omega-3 fatty acid oil body lotion and preparation method thereof |
| CN103141675A (en) * | 2013-03-04 | 2013-06-12 | 哈尔滨福泰永生态农牧产品有限公司 | Functional egg with low total cholesterol content and high HDL (high density lipoprotein)-cholesterol content and production method thereof |
| CN105769919A (en) * | 2016-04-19 | 2016-07-20 | 张山明 | Fish oil composition with function of reducing blood fat and preparation method and application |
-
2007
- 2007-10-30 CN CNA2007101654949A patent/CN101147736A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101982163A (en) * | 2010-10-27 | 2011-03-02 | 中国科学院西双版纳热带植物园 | Omega-3 fatty acid oil body lotion and preparation method thereof |
| CN101982163B (en) * | 2010-10-27 | 2011-11-30 | 中国科学院西双版纳热带植物园 | Omega-3 fatty acid oil body lotion and preparation method thereof |
| CN103141675A (en) * | 2013-03-04 | 2013-06-12 | 哈尔滨福泰永生态农牧产品有限公司 | Functional egg with low total cholesterol content and high HDL (high density lipoprotein)-cholesterol content and production method thereof |
| CN103141675B (en) * | 2013-03-04 | 2014-07-02 | 哈尔滨福泰永生态农牧产品有限公司 | Functional egg with low total cholesterol content and high HDL (high density lipoprotein)-cholesterol content and production method thereof |
| CN105769919A (en) * | 2016-04-19 | 2016-07-20 | 张山明 | Fish oil composition with function of reducing blood fat and preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4407821A (en) | Lipidic compositions for use in dietetics, reanimation and therapeutics | |
| US11406602B2 (en) | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof | |
| US5502077A (en) | Fatty acid composition | |
| EP1390025B1 (en) | Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders | |
| US20090182049A1 (en) | Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans | |
| JP2008521863A (en) | Use of omega-3 fatty acids to treat hypercholesterolemia caused by antiretroviral therapy in HIV-infected patients | |
| JPS60115522A (en) | Composite fatty acid composition for lowering cholesterol and triglyceride level in blood | |
| WO2008006607A2 (en) | Pharmaceutical and nutraceutical products comprising vitamin k2 | |
| US20120201912A1 (en) | Substances for reducing occurrence of major cardiac events comprising omega-3 polyunsaturated fatty acid or derivatives thereof and high-monacolin k content red yeast rice extract | |
| CN101147736A (en) | Composition capable of reducing blood lipoid and lowering cholesterol | |
| JPH04290822A (en) | Allergy preventing medicine and food | |
| CN102232430A (en) | Health-care oil | |
| Gazi et al. | Beneficial effects of omega-3 fatty acids: the current evidence | |
| CN101194913A (en) | Natural seal oil compression biological preparation for treating hyperlipidemia and technique of preparing the same | |
| Lyu | The effects of Omega-3 fatty acids on Heart diseases | |
| CN102631370A (en) | Composition for preventing or improving hyperlipidemia and supplementing vitamin D | |
| Hadzhieva et al. | Omega-3 polyunsaturated fatty acids metabolism and prevention of some socially significant diseases | |
| JP2005206476A (en) | Prophylactic or ameliorating agent for liver disease accompanied with hepatopathy | |
| Abdel-Halim et al. | Effect of flaxseed and corn oils on acute myocardial infarction in high fat diet fed rat | |
| Abdel-Halim et al. | Effect of flaxseed and corn oils on acute myocardial infarction in high fat diet fed rat | |
| CN109805411A (en) | A kind of health food assisting reducing blood lipid | |
| Anurag et al. | Omega 3: An Effective Nutritional Dietary Supplement | |
| AU2002255167B2 (en) | Coenzyme Q and eicosapentaenoic acid (EPA) | |
| WO2013138407A1 (en) | Substances for reducing occurrence of major cardiac events comprising epa or derivatives thereof, optionally, dha or derivatives thereof and monacolin k | |
| CN104814948A (en) | Blood fat lowering capsules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080326 |